Capital Partners Iii Gp, L.... Net Worth

The estimated Net Worth of Capital Partners Iii Gp, L.... is at least $17.5 Milhão dollars as of 13 January 2020. Capital L owns over 1,250,000 units of Osmotica Pharmaceuticals Plc stock worth over $17,461,259 and over the last 5 years Capital sold OSMT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital L OSMT stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Osmotica Pharmaceuticals Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital bought 1,250,000 units of OSMT stock worth $6,250,000 on 13 January 2020.

The largest trade Capital's ever made was buying 1,250,000 units of Osmotica Pharmaceuticals Plc stock on 13 January 2020 worth over $6,250,000. On average, Capital trades about 1,250,000 units every 0 days since 2020. As of 13 January 2020 Capital still owns at least 15,730,864 units of Osmotica Pharmaceuticals Plc stock.

You can see the complete history of Capital L stock trades at the bottom of the page.

Insiders trading at Osmotica Pharmaceuticals Plc

Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman, eLtd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.

What does Osmotica Pharmaceuticals Plc do?

Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.

Complete history of Capital L stock trades at Osmotica Pharmaceuticals Plc

Osmotica Pharmaceuticals Plc executives and stock owners

Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include:

• Brian Markison,
  Chairman of the Board, Chief Executive Officer
• Christopher Klein,
  General Counsel, Secretary
• Tina deVries,
  Executive Vice President - Research & Development
• James Schaub,
  Chief Operating Officer, Executive Vice President
• Brian A. Markison,
  Chairman, Pres & CEO
• Christopher A. Klein,
  Gen. Counsel & Sec.
• James D. Schaub,
  Exec. VP & COO
• Dr. Tina Marie deVries,
  Exec. VP of R&D
• Andrew Einhorn,
  Chief Financial Officer
• Fred Weiss,
  Independent Director
• Gregory Cowan,
  Independent Director
• David Burgstahler,
  Director
• Sriram Venkataraman,
  Director
• Juan Vergez,
  Director
• Michael DeBiasi,
  Independent Director
• Lisa Wilson,
  IR Contact Officer
• Joachim Benes,
  Director
• Andrew J. Einhorn CPA,
  Chief Financial Officer
• Jarret Miller,
  Exec. VP of HR
• Sergio Alegre,
  VP of Global Compliance
• Capital Partners Iii Gp, L....,
  
• Ltd Orbit Co Invest A 1 Llc...,
  
• Foundation Harsaul,
  10% owner
• Capital Partners Iii Gp, L....,